Inhibikase Therapeutics, Inc. (IKT) announced it will meet with the Office of Cardiology, Hematology, Endocrinology and Nephrology in the Division of Cardiology and Nephrology at the FDA for a Pre-IND meeting to discuss IkT-001Pro as a treatment for Pulmonary Arterial Hypertension.